CLINICAL STUDY: HYPERTENSION
Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function
Yukihito Higashi, MD, PhD*,
Shota Sasaki, MD*,
Keigo Nakagawa, MD*,
Hideo Matsuura, MD, PhD*,
Goro Kajiyama, MD, PhD* and
Tetsuya Oshima, PhD
* First Department of Internal Medicine, Hiroshima University School of Medicine, Hiroshima, Japan
Department of Clinical Laboratory Medicine, Hiroshima University School of Medicine, Hiroshima, Japan
Manuscript received June 7, 2000;
revised manuscript received September 22, 2000,
accepted November 3, 2000.
Reprint requests and correspondence: Dr. Yukihito Higashi, Hiroshima University School of Medicine, First Department of Internal Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan yhigashi{at}mcai.med.hiroshima-u.ac.jp
OBJECTIVES
The purpose of this study was to evaluate the effects of the angiotensin-converting enzyme (ACE) inhibitor imidapril and the calcium antagonist amlodipine on endothelial function before and after 2, 4, 8, 12, 24 and 48 weeks of treatment.
BACKGROUND
There are limited data on whether and how long endothelial function is improved after initiation of ACE inhibitor treatment and how the grade of endothelial function further progresses after improvement of endothelial dysfunction in patients with essential hypertension.
METHODS
The forearm blood flow (FBF) was measured in 25 patients with essential hypertension and in 25 normotensive subjects by using strain-gauge plethysmography during reactive hyperemia (RH) (280 mm Hg for 5 min) and after sublingual administration of nitroglycerin (NTG, 0.3 mg).
RESULTS
The FBF of patients with essential hypertension during RH was significantly less than that of normotensive subjects. The increase in FBF after sublingual NTG was similar in both groups. Both imidapril (n = 13) and amlodipine (n = 12) significantly reduced systolic blood pressure and diastolic after eight weeks of treatment from the pretreatment values. Forearm vascular resistance was significantly decreased after two weeks of treatment. Imidapril significantly augmented RH after 12 weeks of treatment from the pretreatment values (31.6 ± 5.7 to 38.2 ± 6.0 ml/min per 100 ml tissue, p < 0.05), whereas amlodipine did not alter RH for each treatment period. The ability of imidapril to improve RH was maintained throughout the 48-week treatment period. There was no significant difference in RH at 12, 24 and 48 weeks. The increase in FBF after sublingual administration of NTG was similar in all treatment periods for the two groups. The infusion of NG-monomethyl-L-arginine, a nitric oxide (NO) synthase inhibitor, abolished the enhancement of RH in hypertensive patients treated with imidapril.
CONCLUSIONS
These findings suggest that the ACE inhibitor imidapril augments RH after 12 weeks of treatment in patients with essential hypertension and that this ACE inhibitor-induced augmentation of RH may be due to an increase in NO.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | BP | = blood pressure | | EDHF | = endothelium-dependent hyperpolarizing factor | | FBF | = forearm blood flow | | FVR | = forearm vascular resistance | | L-NMMA | = NG-monomethyl-L-arginine | | NO | = nitric oxide | | NTG | = nitroglycerin | | RH | = reactive hyperemia |
|
This article has been cited by other articles:

|
 |

|
 |
 
D. Tousoulis, C. Antoniades, K. Marinou, C. Vasiliadou, G. Bouras, E. Stefanadi, G. Latsios, G. Siasos, K. Toutouzas, and C. Stefanadis
Methionine-Loading Rapidly Impairs Endothelial Function, by Mechanisms Independent of Endothelin-1: Evidence for an Association of Fasting Total Homocysteine with Plasma Endothelin-1 Levels
J. Am. Coll. Nutr.,
June 1, 2008;
27(3):
379 - 386.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Toda, K. Ayajiki, and T. Okamura
Interaction of Endothelial Nitric Oxide and Angiotensin in the Circulation
Pharmacol. Rev.,
March 1, 2007;
59(1):
54 - 87.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Antoniades, D. Tousoulis, K. Marinou, C. Vasiliadou, C. Tentolouris, G. Bouras, C. Pitsavos, and C. Stefanadis
Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines.
Am. J. Clinical Nutrition,
October 1, 2006;
84(4):
781 - 788.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Tousoulis, C. Antoniades, C. Vassiliadou, M. Toutouza, C. Pitsavos, C. Tentolouris, A. Trikas, and C. Stefanadis
Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure
Eur J Heart Fail,
December 1, 2005;
7(7):
1126 - 1132.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Maas
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA)
Vascular Medicine,
July 1, 2005;
10(1_suppl):
S49 - S57.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Maas
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA)
Vascular Medicine,
May 1, 2005;
10(2_suppl):
S49 - S57.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D Tousoulis, C Antoniades, and C Stefanadis
Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques
Heart,
April 1, 2005;
91(4):
553 - 558.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Oliver and D. J. Webb
Noninvasive Assessment of Arterial Stiffness and Risk of Atherosclerotic Events
Arterioscler Thromb Vasc Biol,
April 1, 2003;
23(4):
554 - 566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sanada, Y. Higashi, K. Nakagawa, M. Tsuda, I. Kodama, M. Kimura, K. Chayama, and K. Ohama
A Comparison of Low-Dose and Standard-Dose Oral Estrogen on Forearm Endothelial Function in Early Postmenopausal Women
J. Clin. Endocrinol. Metab.,
March 1, 2003;
88(3):
1303 - 1309.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Wassmann, S. Hilgers, U. Laufs, M. Bohm, and G. Nickenig
Angiotensin II Type 1 Receptor Antagonism Improves Hypercholesterolemia-Associated Endothelial Dysfunction
Arterioscler Thromb Vasc Biol,
July 1, 2002;
22(7):
1208 - 1212.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Higashi, S. Sasaki, K. Nakagawa, H. Matsuura, T. Oshima, and K. Chayama
Endothelial Function and Oxidative Stress in Renovascular Hypertension
N. Engl. J. Med.,
June 20, 2002;
346(25):
1954 - 1962.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|